BJU international · 2026
[18F]fluorodeoxyglucose PET/CT refines staging and treatment selection in high-risk upper tract urothelial carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lijnen Renee A G, Ringia Joanneke B, Hendricksen Kees, Vogel Wouter V, Boellaard Thierry N, van der Heijden Michiel S, Braat Arthur J A T, van Rhijn Bas W G, Mertens Laura S
Аннотация
OBJECTIVES: To evaluate the incremental clinical value of [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) beyond contrast-enhanced computed tomography (CECT) for primary staging of suspected high-risk upper tract urothelial carcinoma (UTUC).
PATIENTS AND METHODS: We conducted a consecutive paired-imaging cohort study of patients with suspected high-risk UTUC undergoing primary staging with both CECT and [18F]FDG-PET/CT at a tertiary cancer centre between 2013 and 2025. The primary outcome was clinically relevant stage migration, defined as a transition between non-metastatic and metastatic disease, and its impact on multidisciplinary treatment recommendation. Secondary outcomes included diagnostic performance in cases with histopathological verification.
RESULTS: Among 203 patients, [18F]FDG-PET/CT resulted in stage migration in 45 (22%), predominantly through upstaging (39 patients [19%]), comprising regional nodal upstaging in 19 patients (9.4%) and distant metastatic upstaging in 22 (11%), with both occurring in two patients. [18F]FDG-PET/CT led to treatment modification in 43 patients (21%). Stage migration was more frequent in the presence of CECT-suspicious lymph nodes (odds ratio 3.4, 95% confidence interval 1.6-7.3). Among the 62 patients with histopathological verification, [18F]FDG-PET/CT demonstrated significantly higher sensitivity for nodal metastases than CECT (74% vs 33%) with similar specificity (89% vs 86%). Limitations include the retrospective single-centre design and incomplete pathological confirmation, mostly due to neoadjuvant treatment and omission of surgery in metastatic disease.
CONCLUSION: [18F]FDG-PET/CT provides actionable staging information beyond CECT in high-risk UTUC, leading to treatment modification in one in five patients and in half of those with CECT-suspicious nodal disease. These findings support selective use of [18F]FDG-PET/CT in primary staging to refine treatment selection.
PATIENTS AND METHODS: We conducted a consecutive paired-imaging cohort study of patients with suspected high-risk UTUC undergoing primary staging with both CECT and [18F]FDG-PET/CT at a tertiary cancer centre between 2013 and 2025. The primary outcome was clinically relevant stage migration, defined as a transition between non-metastatic and metastatic disease, and its impact on multidisciplinary treatment recommendation. Secondary outcomes included diagnostic performance in cases with histopathological verification.
RESULTS: Among 203 patients, [18F]FDG-PET/CT resulted in stage migration in 45 (22%), predominantly through upstaging (39 patients [19%]), comprising regional nodal upstaging in 19 patients (9.4%) and distant metastatic upstaging in 22 (11%), with both occurring in two patients. [18F]FDG-PET/CT led to treatment modification in 43 patients (21%). Stage migration was more frequent in the presence of CECT-suspicious lymph nodes (odds ratio 3.4, 95% confidence interval 1.6-7.3). Among the 62 patients with histopathological verification, [18F]FDG-PET/CT demonstrated significantly higher sensitivity for nodal metastases than CECT (74% vs 33%) with similar specificity (89% vs 86%). Limitations include the retrospective single-centre design and incomplete pathological confirmation, mostly due to neoadjuvant treatment and omission of surgery in metastatic disease.
CONCLUSION: [18F]FDG-PET/CT provides actionable staging information beyond CECT in high-risk UTUC, leading to treatment modification in one in five patients and in half of those with CECT-suspicious nodal disease. These findings support selective use of [18F]FDG-PET/CT in primary staging to refine treatment selection.